LABORATORY RESEARCH Inhibition of Microvesiculation Sensitizes Prostate Cancer Cells to Chemotherapy and Reduces Docetaxel Dose Required to Limit Tumor Growth In Vivo To see whether such drugs could be used at lower concentrations with the same efficacy, investigators showed that microvesiculation of prostate cancer cells could be inhibited pharmacologically with calpeptin and by siRNA. [Sci Rep] Full Article The Inhibitory Effects of AR/miR-190a/YB-1 Negative Feedback Loop on Prostate Cancer and Underlying Mechanism The authors first observed AR/miR-190a/YB-1 forms an auto-regulatory negative feedback loop in prostate cancer: miR-190a expression was down-regulated by AR activation; YB-1 functions are as an AR activator; miR-190a inhibited AR expression and transactivation through direct binding to 3′UTR of YB-1 gene. [Sci Rep] Full Article Discovery of Potent 17β-Hydroxywithanolides for Castration-Resistant Prostate Cancer by High-Throughput Screening of a Natural Products Library for Androgen-Induced Gene Expression Inhibitors Investigators demonstrated the successful application of a high-throughput gene-expression profiling assay directly targeting genes of the androgen receptor pathway to screen a natural products library leading to the identification of 17β-hydroxywithanolides 1-5 of which physachenolide D exhibited potent and selective in vitro activity against the prostate cell lines, LNCaP and PC-3. [J Med Chem] Abstract PAX2 Promoted Prostate Cancer Cell Invasion through Transcriptional Regulation of HGF in an In Vitro Model Using an in vitro invasion model, scientists found that paired box 2 (PAX2) and hepatocyte growth factor (HGF) promoted prostate cancer cell invasion in the same pathway. They found that PAX2 protein activated the HGF gene promoter through histone H3 acetylation and upregulated HGF gene expression. [Biochim Biophys Acta] Abstract Hsa-miR-146a-5p Modulates Androgen-Independent Prostate Cancer Cells Apoptosis by Targeting ROCK1 Scientists demonstrated that microRNA (miR)-146a was down-regulated in androgen-independent prostate cancer (PC) tissues and cell lines compared to that in the androgen-dependent PC tissues. [Prostate] Abstract The Transcription Factor ERG Increases Expression of Neurotransmitter Receptors on Prostate Cancer Cells To investigate the role of ERG, LNCaP and PC3 cells were transfected with ERG and gene expression and metabolic profile were analyzed. [BMC Cancer] Full Article Mitotic Arrest Induced in Human DU145 Prostate Cancer Cells in Response to KHC-4 Treatment The antitumor activity of KHC-4 was analyzed using human prostate cancer (CaP) cells and the underlining anticancer mechanisms of KHC-4 were identified. KHC-4 inhibited cell proliferation and induced cytotoxicity in the castration-resistant CaP DU145 cell line. [Environ Toxicol] Abstract Pristimerin Inhibits Prostate Cancer Bone Metastasis by Targeting PC-3 Stem Cell Characteristics and VEGF-Induced Vasculogenesis of BM-EPCs The effect of Pristimerin on PC-3 stem cell characteristics and metastasis were detected by spheroid formation, CD133 and CD44 protein expression, matrix-gel invasive assay and colony-formation assay in vitro, VEGF and pro-inflammatory cytokines expression by ELISA assay, and tumor tumorigenicity by X-ray and MR in NOD-SCID mice model in vivo. [Cell Physiol Biochem] Full Article A Role for the Dehydrogenase DHRS7 (SDR34C1) in Prostate Cancer Researchers characterized the effects of siRNA-mediated DHRS7 knockdown on the properties of three distinct human prostate cell lines. The siRNA-mediated knockdown of DHRS7 expression in the human prostate cancer cell lines LNCaP, BPH1, and PC3 significantly increased cell proliferation in LNCaP cells as well as cell migration in all of the investigated cell lines. [Cancer Med] Full Article CLINICAL RESEARCH Phase Ib Placebo-Controlled, Tissue Biomarker Trial of Diindolylmethane (BR-DIMNG) in Patients with Prostate Cancer Who Are Undergoing Prostatectomy Investigators performed a multicenter, double-blind, placebo-controlled trial of 3,3′-diindolylmethane in patients diagnosed with prostate cancer and scheduled for radical prostatectomy. [Eur J Cancer Prev] Abstract |